Glucosephosphate Dehydrogenase
"Glucosephosphate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005954
|
| MeSH Number(s) |
D08.811.682.047.150.300
|
| Concept/Terms |
Glucosephosphate Dehydrogenase- Glucosephosphate Dehydrogenase
- Dehydrogenase, Glucosephosphate
- Glucose-6-Phosphate Dehydrogenase
- Dehydrogenase, Glucose-6-Phosphate
- Glucose 6 Phosphate Dehydrogenase
|
Below are MeSH descriptors whose meaning is more general than "Glucosephosphate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Glucosephosphate Dehydrogenase".
This graph shows the total number of publications written about "Glucosephosphate Dehydrogenase" by people in this website by year, and whether "Glucosephosphate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosephosphate Dehydrogenase" by people in Profiles.
-
Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres. J Neurooncol. 2022 Dec; 160(3):677-689.
-
Hemolysis After Medication Exposure in Pediatric Patients With G6PD Deficiency. J Pediatr Hematol Oncol. 2022 07 01; 44(5):261-263.
-
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19. Pharmacogenomics J. 2021 12; 21(6):649-656.
-
NF-?B-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat Immunol. 2021 02; 22(2):193-204.
-
Forced expression of miR-143 and -145 in cardiomyocytes induces cardiomyopathy with a reductive redox shift. Cell Mol Biol Lett. 2020; 25:40.
-
Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020 04; 22(4):476-486.
-
Inhibition of ERRa Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. Cell Rep. 2019 06 18; 27(12):3587-3601.e4.
-
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatr Blood Cancer. 2019 06; 66(6):e27681.
-
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39.
-
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol. 2013 Jul; 88(7):571-6.